Tonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025
Provided By GlobeNewswire
Last update: Jul 7, 2025
Single dose vaccination with TNX-801 protects animals from a lethal challenge with monkeypox, the causative agent of mpox
TNX-801 confers durable protection after a single dose
Read more at globenewswire.com51.35
-8.23 (-13.81%)
Find more stocks in the Stock Screener
TNXP Latest News and Analysis
